Research and treatment options for ankylosing spondylitis are being explored and discussed. Some pharmaceutical companies, such as Lynk, are completing phase iii enrolment for potential treatments, while others are expanding reimbursement for existing oral therapies. Additionally, various studies and guides are being published to inform patients and healthcare providers about the condition and its evolving treatment landscape.